Other Cancers Efficiency & Safety of Pelabresib (CPI-0610) Add-On to Ruxolitinib in Myelofibrosis Sep 04, 2023
Other Cancers Ide-Cel in Patients with Inadequate Response to Frontline Autologous Stem Cell Transplantation Sep 04, 2023
Other Cancers Ixazomib vs. Lenalidomide or Ixazomib + Lenalidomide Combination for Transplant-Ineligible Multiple Myeloma Sep 04, 2023
Lymphoma Anti-CD38 Monoclonal Antibody CM313 in Relapsed/Refractory Multiple Myeloma or Lymphoma Patients Sep 04, 2023
Other Cancers Interim Analysis of the LAUNCH Study: Selinexor, Dexamethasone, and Chemotherapy in Relapsed Multiple Myeloma Sep 04, 2023
Other Cancers Elranatamab Alone or with Daratumumab vs. Daratumumab + Pomalidomide + Dexamethasone in R/R Multiple Myeloma Sep 04, 2023
